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INTRODUCTION
Prevalence of diabetes mellitus increases in Turkey and worldwide (1) . Diabetic foot ulcer (DFU) is a serious complication related mortality. These lesions are huge social and economical problems for health care systems. The main etiologies of ulcers are neuropathy, ischemia and infections (2) .
Treatment of DFU is complex and difficult. Blood glucose regulation, debridment and surgical revascularization are used in management. Hyperbaric oxygen treatment (HBOT) is a method whose effect is shown. HBOT increases healing and decreases amputation (3, 4) .
In negative pressure wound therapy (NPWT), the wound is covered with a sterile gauze or sponge.
Negative pressure is performed continuously or intermittently. The action mechanism is not clearly understood yet. But affect can be easily observed rapidly (5) . Numerous randomized controlled trials show benefits of healing faster and decreasin amputation by NPWT (6,7).
Intralesional Epidermal Growth Factor (EGF-IL) is a new treatment approach for diabetic foot ulcers. EGF is released from platelets, macrophages, monocytes, and fibroblasts. It has serious role for healing. This approach isn't routine yet and hasn't high evidence with studies (8).
MATERIAL AND METHOD
Eight patients with diabetic foot ulcers followed in Kırıkkale University between 2014-2016 retrospectively. Two patients were female, six patients were male. Patients mean age was 60,3±9,3. The patients were treated with different types of therapies beforedoses. Patients characteristics was showed in table 1. EGF-IL treatment was performed between 5-12 doses. Patients demographics, ulcer place and Wagner stage are given in Table 1 . In a study 25 μgr EGF-IL was applied 3 times per week for 8 weeks to 29 patients who were at high risk of amputation due to Wagner 3 or 4 grade le- 
RESULTS
sions. Prior to EGF application, all ulcers were followed for 15 or 25 days with sharp debridements and conventional therapy but remained refractory. Granulation tissue growth was observed after the eighth application in 86% of patients. After the 24th application, amputation was avoided in 17 patients (58%). Reepithelization was observed in 77% of patients, at an average of 66 days. At 1-year followup, relapse was seen only in 1 patient. The authors concluded that amputation rates could reduce by EGF-IL application in DFUs (8) . In a multicentered double-blind placebo-controlled Phase III clinical study, intralesional application of 75 μg and 25 μg EGF doses and placebo were compared. Both doses were proven to be more efective than placebo. EGF-IL as 75 μg was obtained more effective than 25 μgr EGF-IL significantly on wound healing (12) .
In another study the efects of 75 ug EGF-IL was studied on diabetic ulcers. Thirty-two patients with either Wagner grade 3 or 4 ulcers was treated with EGF-IL three times a week for 8 weeks. Nine pateients' Wagner grade 3 ulcers healed with full cicatrization and granulation, one underwent amputation. In Wagner grade 4 group, 20 patients' wound healed totally and 2 patients required amputation. Treatment duration was 46.5±8.9 days (13).
In our study, EGF-IL treatment was showed achievement the other studies. NPWT and surgical interventions were applied to patients and combine with EGF. Treatment was expensive but effective in patients which prior treatment was unsuccesful.
In our experience on patients wounds which priorly have healing problems, improved with intralesional EGF. This treatment is expensive and caused of some allergic reactions. Relation with malignancies are not known for long-term. In our opinion intralesional EGF treatment should be used wounds which were not healed with the other treatments.
